Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.

NCT01301456 · ClinicalTrials.gov registry record · Phase 1

Single-Dose And Multiple-Dose Safety And Tolerability Study Of PF-04856883 In Type 2 Diabetic Adult Females

A Phase 1 study of Diabetes Mellitus, Type 2 and Diabetes Mellitus, sponsored by Pfizer.

Completed
Registry status
Phase 1
Development phase
84
Enrollment target
7
Study locations

NCT01301456 is a Phase 1 study of Diabetes Mellitus, Type 2 and Diabetes Mellitus that has completed, run by Pfizer. The registered enrollment target is 84 participants, below the 4,485-participant average among 348 other Diabetes Mellitus, Type 2 trials with a reported enrollment target (98% lower). The trial reports 7 study locations across 6 states.

View on ClinicalTrials.gov ↗

View your shortlist →

The verdict

NCT01301456, a Phase 1 study of Diabetes Mellitus, Type 2 and Diabetes Mellitus, has completed, sponsored by Pfizer.

COMPLETED
Registry status
Phase 1
Development phase
84 participants
Enrollment target
7
Study locations

Study Summary

The primary objective of this study is to evaluate the safety and tolerability of PF-04856883 (CVX-096) in adult female subjects with Type 2 diabetes mellitus on high dose of metformin.

Interventions

  • BIOLOGICAL Placebo
  • BIOLOGICAL PF-04856883

Study Locations (7)

Florida

  • Elite Research Institute - Miami
  • Comprehensive Phase One (A Division of Comprehensive NeuroScience, Inc.) - Miramar

California

  • Profil Institute for Clinical Research, Inc. - Chula Vista

Georgia

  • Atlanta Center for Medical Research - Atlanta

Nebraska

  • ICON Clinical Pharmacology, LLC - Omaha

Pennsylvania

  • CRI Worldwide, LLC - Philadelphia

Texas

  • Healthcare Discoveries LLC d/b/a ICON Development Solutions - San Antonio

Trial Details

FieldValue
Enrollment Target 84 participants
Start Date 2011-03
Est. Completion 2012-04
Phase Phase 1

Sponsor

Pfizer

1,845 total trials

What the Registry Record Tells You About NCT01301456

The ClinicalTrials.gov registry entry for NCT01301456 describes a study currently listed as completed, categorized as Phase 1. The registered enrollment target is 84 participants, a figure that helps gauge the scale of data the investigators plan to collect, below the 4,485-participant average among 348 other Diabetes Mellitus, Type 2 trials with a reported enrollment target (98% lower). The listed sponsor is Pfizer, which has 1,845 total studies on file at ClinicalTrials.gov.

The record links to 5 conditions, with Diabetes Mellitus, Type 2 appearing as the primary indexed condition, and to 2 interventions - of which Placebo is the first listed.

NCT01301456 reports 7 study locations spanning 6 distinct geographic areas - top geographies include Florida, California, Georgia.

Frequently Asked Questions

What is clinical trial NCT01301456 about?

NCT01301456 is a clinical study titled "Single-Dose And Multiple-Dose Safety And Tolerability Study Of PF-04856883 In Type 2 Diabetic Adult Females". The primary objective of this study is to evaluate the safety and tolerability of PF-04856883 (CVX-096) in adult female subjects with Type 2 diabetes mellitus on high dose of metformin.

What is the current status of trial NCT01301456?

This trial is currently completed. It is a Phase 1 study. The enrollment target is 84 participants. The study started on 2011-03. Estimated completion is 2012-04.

What conditions does trial NCT01301456 study?

This clinical trial studies the following conditions: Diabetes Mellitus, Type 2, Diabetes Mellitus, Glucose Metabolism Disorders, Metabolic Diseases, Endocrine System Diseases.

What interventions are being tested in trial NCT01301456?

The interventions under investigation include: Placebo (BIOLOGICAL), PF-04856883 (BIOLOGICAL).

Who is sponsoring clinical trial NCT01301456?

This trial is sponsored by Pfizer, which has 1,845 total clinical trials registered on ClinicalTrials.gov.

Where is trial NCT01301456 being conducted?

This trial has 7 study locations across California, Florida, Georgia, Nebraska, Pennsylvania. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.

Similar trials for Diabetes Mellitus, Type 2

Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.

Data sourced from official public datasets. See our methodology for details. Retrieved and formatted by PlainTrial Editorial

Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.